NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Clinical trials for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye implant shows promise for Long-Term wet AMD control
Disease control Recruiting nowThis study is checking the long-term safety of an implant called OTX-TKI (axitinib) for people with wet age-related macular degeneration (AMD). The implant is placed in the eye and slowly releases medicine to control the disease. About 850 people who already completed two years o…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Ocular Therapeutix, Inc. • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
One-Shot gene therapy could replace frequent eye injections for wet AMD
Disease control Recruiting nowThis phase 3 study tests a single injection of Ixo-vec gene therapy against standard aflibercept injections in 284 people with wet AMD. The goal is to see if Ixo-vec can maintain or improve vision while reducing the need for repeated eye injections. Participants must be at least …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New eye injection shows promise for wet AMD in everyday practice
Disease control Recruiting nowThis observational study will follow 300 people with wet age-related macular degeneration (nAMD) who receive aflibercept 8 mg injections as part of their routine care. Researchers want to see how well the drug improves vision and reduces retinal swelling over 12 months, and what …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
One shot to save sight? gene therapy trial aims to end frequent eye injections for wet AMD
Disease control Recruiting nowThis Phase 3 trial tests a single injection of 4D-150, a gene therapy, in 480 adults with wet age-related macular degeneration (AMD). The goal is to see if one treatment can maintain or improve vision and reduce the need for standard anti-VEGF injections like Eylea. Participants …
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Gene therapy shot could end monthly eye injections for wet AMD
Disease control Recruiting nowThis Phase 3 trial tests a single injection of LX102 gene therapy under the retina for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. About 332 participants will receive either LX102 or standard aflibercept injections. The goal is to see i…
Matched conditions: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
Phase: PHASE3 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC